Cidara Therapeutics/ US1717572069 /
2024-05-10 4:43:24 PM | Chg. 0.00 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
12.68USD | 0.00% | 100 Turnover: 1,268 |
-Bid Size: - | -Ask Size: - | 12.68 | 12.68 |
GlobeNewswire
05-11
CDTX INVESTOR ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cidara Therapeutics, Inc. Investors t...
GlobeNewswire
04-26
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388...
GlobeNewswire
04-26
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on...
GlobeNewswire
04-24
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Priva...
GlobeNewswire
04-24
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Cl...
GlobeNewswire
04-22
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financia...
GlobeNewswire
04-05
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the America...
GlobeNewswire
03-06
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at Ame...
GlobeNewswire
02-12
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
GlobeNewswire
01-29
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidia...
GlobeNewswire
2023-12-22
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasi...
GlobeNewswire
2023-12-07
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates a...
GlobeNewswire
2023-12-06
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in Chi...
GlobeNewswire
2023-11-30
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO ...
GlobeNewswire
2023-11-03
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annua...
GlobeNewswire
2023-11-02
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire
2023-10-13
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment o...
GlobeNewswire
2023-10-11
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at I...
GlobeNewswire
2023-09-29
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-09-27
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
GlobeNewswire
2023-09-07
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeli...
GlobeNewswire
2023-09-06
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference